Switch theme
Sign up to access all valuation multiples
Provexis PLC is a British food company. It is engaged in developing and licensing the Fruitflow, which is patented, natural, breakthrough ingredient which helps with platelet aggregation. Fruitflow reduces the propensity for aberrant blood clotting, typically associated with cardiovascular disease, which can result in heart attack and stroke. The extract is available in two formats, a syrup and a powder, and it can be included in a broad range of food, beverage and dietary supplement formats.
2004
2
Last FY Revenue $1.1M
Last FY EBITDA -$0.8M
$15.0M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, Provexis achieved revenue of $1.1M and an EBITDA of -$0.8M.
Provexis expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Provexis valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $1.1M | XXX | XXX | XXX |
| Gross Profit | XXX | $0.4M | XXX | XXX | XXX |
| Gross Margin | XXX | 35% | XXX | XXX | XXX |
| EBITDA | XXX | -$0.8M | XXX | XXX | XXX |
| EBITDA Margin | XXX | -75% | XXX | XXX | XXX |
| EBIT | XXX | -$0.8M | XXX | XXX | XXX |
| EBIT Margin | XXX | -75% | XXX | XXX | XXX |
| Net Profit | XXX | -$0.8M | XXX | XXX | XXX |
| Net Margin | XXX | -73% | XXX | XXX | XXX |
| Net Debt | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Provexis's stock price is GBP 0 (or $0).
Provexis has current market cap of GBP 11.7M (or $15.7M), and EV of GBP 11.2M (or $15.0M).
See Provexis trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $15.0M | $15.7M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Provexis has market cap of $15.7M and EV of $15.0M.
Provexis's trades at 16.0x EV/Revenue multiple, and -20.1x EV/EBITDA.
Equity research analysts estimate Provexis's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Provexis's P/E ratio is not available.
See valuation multiples for Provexis and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $15.7M | XXX | $15.7M | XXX | XXX | XXX |
| EV (current) | $15.0M | XXX | $15.0M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 16.0x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -20.1x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | -20.1x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | -21.8x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -40.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialProvexis's revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $0.6M for the same period.
Provexis's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Provexis's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Provexis and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.5M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.6M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 8% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 38% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 111% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| SynBiotic | XXX | XXX | XXX | XXX | XXX | XXX |
| Mega Lifesciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Procter & Gamble Health | XXX | XXX | XXX | XXX | XXX | XXX |
| Abbott India | XXX | XXX | XXX | XXX | XXX | XXX |
| Sanofi India | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Provexis acquired XXX companies to date.
Last acquisition by Provexis was XXXXXXXX, XXXXX XXXXX XXXXXX . Provexis acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Provexis founded? | Provexis was founded in 2004. |
| Where is Provexis headquartered? | Provexis is headquartered in United Kingdom of Great Britain and Northern Ireland. |
| How many employees does Provexis have? | As of today, Provexis has 2 employees. |
| Who is the CEO of Provexis? | Provexis's CEO is Mr. Ian Ford. |
| Is Provexis publicy listed? | Yes, Provexis is a public company listed on LON. |
| What is the stock symbol of Provexis? | Provexis trades under PXS ticker. |
| When did Provexis go public? | Provexis went public in 2004. |
| Who are competitors of Provexis? | Similar companies to Provexis include e.g. SynBiotic, Mega Lifesciences, Procter & Gamble Health, Abbott India. |
| What is the current market cap of Provexis? | Provexis's current market cap is $15.7M |
| Is Provexis profitable? | Yes, Provexis is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
